TABLE 3.
Outcome Data
| Best Response | Bevacizumab + IFN |
|---|---|
| Partial response (PR) | 0 |
| Stable disease (SD) | 3 |
| Progressive disease (PD) | 2 |
| Progression free survival (wk) | |
| Mean | 18 |
| Range | 6–36 |
| Overall survival (wk) | |
| Mean | 43 |
| Range | 7–91 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.